Status:
UNKNOWN
Clinical Controlled Study on the Efficacy of Denosumab in Treating Osteoporosis in the Domestic Population and Its Impact on Sarcopenia-related Outcomes
Lead Sponsor:
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Conditions:
Sarcopenia
Osteoporosis
Eligibility:
All Genders
40+ years
Phase:
PHASE3
Brief Summary
Through the method of a clinical randomized controlled trial, patients meeting the study criteria are randomly assigned to either the Denosumab treatment group or a placebo group. After a treatment pe...
Eligibility Criteria
Inclusion
- Clinical diagnosis of postmenopausal/senile osteoporosis after examination and assessment.
- Clinical diagnosis of postmenopausal/senile osteoporosis combined with sarcopenia after examination and assessment.
- Have not previously taken any other anti-osteoporosis drugs.
Exclusion
- Clinical diagnosis of pathological fractures.
- Have participated in another clinical trial within the past 3 months or have taken other anti-osteoporosis drugs within the past 6 months.
- Severe chronic metabolic diseases or serious organ failure.
Key Trial Info
Start Date :
February 1 2024
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
March 1 2025
Estimated Enrollment :
86 Patients enrolled
Trial Details
Trial ID
NCT06154707
Start Date
February 1 2024
End Date
March 1 2025
Last Update
August 16 2024
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Union Hospital Tongji Medical College Huazhong University of Science and Technology
Wuhan, Hubei, China, 430022